In Congress, I’ll fight to allow Medicare to negotiate drug prices and put a cap on out of pocket costs for medication.
I will fight to allow Medicare to negotiate drug prices and cap out-of-pocket medication costs.
Occurrences
Evidence
The Lowering Drug Costs for American Families Act builds on this important progress, including by allowing Medicare to negotiate more drug prices each year, making those lower prices available to the commercial insurance market, capping people’s annual out-of-pocket costs on prescription drugs and insulin at $35 per month, and closing loopholes made by the Trump Administration that allow manufacturers to avoid negotiating prices for years.
seniors will finally have access to these lower prescription drug prices beginning January 1st ... In 2026 alone, seniors are expected to save about $1.5 billion in out-of-pocket expenses on prescription drugs. ... House Democrats have introduced legislation to build on this program by negotiating more drug prices sooner, making those prices available to more people, and capping out-of-pocket costs.
The bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. In addition, the bill eliminates beneficiary cost-sharing above the annual out-of-pocket spending threshold under the Medicare prescription drug benefit beginning in 2024 and caps annual out-of-pocket spending at $2,000 in 2025 (with annual adjustments thereafter).
The Act requires the Secretary of Health and Human Services (Secretary) to negotiate prices for certain drugs covered under Medicare Part B (physician-administered drugs) and Part D (retail prescription drugs), starting with 10 high-spending, single-source drugs for 2026 and increasing to 20 by 2029. ... Effective in 2025, the Part D benefit is reconfigured to include an annual $2,000 out-of-pocket (OOP) spending cap.
Index record for Rep. Shri Thanedar in the Congressional Record for 2025; no item in the retrieved context establishes a new Medicare drug-pricing action by him in the 2026-04-29 to 2026-05-28 lookback window.
Assessments
The promised policy outcome exists in federal law: Medicare now has authority to negotiate prices for certain drugs, and Medicare Part D beneficiaries have an annual out-of-pocket cap, including the 2025 $2,000 cap and negotiated prices taking effect in 2026. That matches the substance of the promise. However, the evidence provided does not show Shri Thanedar personally wrote, sponsored, or materially advanced the enacted provisions; they were enacted before or without candidate-specific proof in this record. Because the outcome was achieved largely through broader Democratic and congressional action rather than demonstrated Thanedar-specific delivery, this merits partial rather than full credit.